There have been several significant developments in the field of gene therapy over the last 10 years. Here are some notable ones:

Approval of gene therapies: In recent years, several gene therapies have been approved by regulatory agencies such as the FDA, EMA, and Health Canada. Examples of approved gene therapies include Luxturna, Zolgensma, and Kymriah.

Advances in gene editing technology: CRISPR/Cas9 gene editing technology has significantly advanced in recent years, making it more efficient and accurate in making precise changes to DNA. This technology has great potential in the treatment of genetic diseases.

Treatment of rare genetic diseases: Gene therapy has been successful in treating rare genetic diseases such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and Leber congenital amaurosis.

Development of gene therapies for more common diseases: Gene therapy is now being explored as a potential treatment for more common diseases such as hemophilia, sickle cell disease, and beta-thalassemia.

Improved delivery methods: Gene therapy delivery methods have been improved, making it possible to deliver genes to specific tissues or organs in the body. This includes the use of viral vectors, nanoparticles, and electroporation.

Increased investment: The field of gene therapy has received significant investment in recent years, leading to more research and development of new therapies.

Overall, these developments in the field of gene therapy offer hope for treating a wide range of genetic and acquired diseases, and ongoing research will likely lead to even more breakthroughs in the coming years.